Our latest edition of CancerScope: First Person Profile highlights #PalliativeCare pioneer Dr. Jennifer Temel, whose work has transformed the patient experience and improved health care delivery and outcomes. https://t.co/UmjcSoNfHu @MGHCancerCenter @MGHThoracicOnc @OncoAlert

Despite progress, advanced ALK+ lung cancer almost always recurs. By deeply exploring the biology of cancer cells that resist treatment, the new PoweRD 2 Cure ALK+ Lung Cancer TeamLab aims to bend the survival curve for patients - @JessicaJLinMD #RadicalCollaboration

Dr. @IbiayiMD brings us up to speed on systemic strategies for #mesothelioma at #DCLung24. With competing immunotherapy approaches, which is best Join us Saturday, October 19th in downtown Washington, DC for this @IASLC endorsed, one-day #CME meeting! https://t.co/uDu8lfLHPT

Dr. @JessicaJLinMD from @MGHThoracicOnc will discuss advances in targeting #ALK in advanced NSCLC at #DCLung24. Learn about the new wave of drugs! Join us Saturday, October 19th in downtown Washington, DC for this @IASLC endorsed, one-day #CME meeting! https://t.co/uDu8lfMfFr

Dr. @ZPiotrowskaMD from @MGHThoracicOnc will discuss #EGFR in NSCLC and overcoming resistance at #DCLung24. This is a talk you do not want to miss! Join us Saturday, October 19th in downtown Washington, DC for this @IASLC endorsed, one-day #CME meeting! https://t.co/uDu8lfMfFr

Congratulations to @cbmeador for receiving the @ASCO Conquer #Cancer Career Development Award for #research work studying liquid biopsies in #SCLC!

Congratulations to @DrJaimeLaurel on receiving the “40 Under 40 in Cancer” award @ASCO. This achievement recognizes Dr. Schneider’s contributions to the field of cancer as one of the nation’s most promising young oncology professionals impacting lives of many affected by #cancer.

MGH Thoracic crew listening to not one but TWO plenary sessions by outstanding @MGHCancerCenter physicians—Dr. Joseph Greer/Dr. Jennifer Temel and @LeciaSequist. 🙌🎉 So grateful to be training with this group! @MGHThoracicOnc

Dr. @LeciaSequist with a brilliant #ASCO24 discussion of LAURA and #EGFR NSCLC. Do we apply this paradigm now to subtypes with CNS active agents that have long term safety data like #ALK and #RET? I think so!

🚨The future of #ThoracicOncology is in great hands! My co-chair colleague Dr @ChristianRolfo, myself, great faculty mentors, & #IASLC staff are honored to kick off the: “2024 global @IASLC #Academy.” Welcome to an outstanding group of #EarlyCareer #Physicians & #Researchers.

Drs. @LeciaSequist of @MGHCancerCenter and @MGHThoracicOnc and @Colazagasti of @sylvestercancer discuss the I-ELCAP study results and their significance for lung cancer screening, as well as how we can do better.

Great day in Boston as a keynote speaker at the DF/HCC Lung Program Annual Symposium. Thank you for the invitation to be part of it. Enjoyed all the great science and discussion. #SCLC #LCSM @DanaFarber @MGHThoracicOnc @LeciaSequist @cbmeador @JustinGainor @teekayowo @Oser_Lab

Nice clearance of ALK mutations and CNS activity, and favorable safety profile! Hopeful news for patients. @alexdrilon @BenjaminBesseMD @oncoOuLungCA @MLJohnsonMD2 @JulienMazieres @EnriquetaFelip @YYElamin @ShirishGadgeel @DRCamidge @ViolaWZhu @ALKpositiveINT

Excited to share the first presentation of the preliminary activity and safety results on NVL-655, new ALK TKI. Brief recap here. Efficacy in heavily pretreated ALK+ NSCLC. Thanks to @AACR #Targets23 for the opportunity to present, to collaborators, patients @ALKPositiveinc #LCSM

Congratulations to Dr. @DrJaimeLaurel on being invited as a Forbeck Foundation scholar to speak about systemic metabolism and #Cancer! Her #research focuses are identifying metabolic liabilities in #oncogene-driven lung cancers in hopes of developing new therapeutic strategies!

Today in Nature - lung cancer targeted therapies can induce APOBEC3A, which drives evolution of acquired drug resistance. Terrific team effort led by Hata and Lawrence groups in collaboration with @ZPiotrowskaMD @LeciaSequist @JessicaJLinMD @JustinGainor https://t.co/qKxK0cBqTF

And now for another installment of Meet the Grads! 🩺🎓 Name: Alissa Cooper, MD (and @DanaFarber/@MassGenBrigham Chief Fellow!) Hometown: Winchester, MA Subspecialty: Thoracic Oncology @MGHThoracicOnc @MGHCancerCenter Faculty position: Thoracic Oncologist @MSKCancerCenter

Our #Boston ALCSI team had a busy weekend raising #lungcancerawareness at the Mission Hill Farmer’s Market, @Whittier_Boston Health Fair, and the @metropolitanbap Community Day. We had a great time getting to know our community and discussing #earlydetection of #lungcancer!!

How do you address resistance to first-line ROS1 TKI therapy in ROS1 fusion-positive lung cancers? Tune in as @JessicaJLinMD from @MGHThoracicOnc discusses the framework for considering later-line strategies at #TTLC23 @IASLC #LCSM @ros1cancer @ros1dersuk @MGHCancerCenter

@GRecondoMD @JulienMazieres, Satoshi Yoda, many others 🌏 🙏 This @NatureCancer review picks up from where we left off with the ALK review authored w/ @RielyMD in 2017 @CD_AACR https://t.co/8yDDr744gp @ALKLungCancer @ALKpositiveINT #LCSM @MGHThoracicOnc @MGHCancerCenter [3/3]